Compare Abbott Laboratories (ABT) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Northrop Grumman Corporation — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Northrop Grumman Corporation trades at $542.87 (market cap $77.98B). The key difference: Abbott Laboratories is far larger — about 2.1× Northrop Grumman Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NOC | |
|---|---|---|
Market Cap | $166.94B | $77.98B |
Sector | Health | Industrials |
52-Week High | $136.62 | $768.02 |
52-Week Low | $82.57 | $496.02 |
Enterprise Value | $193.69B | $92.21B |
Dividend Yield | 2.63% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Northrop Grumman (NOC) trades at $549.04, showing minimal daily movement. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 10.8% net income margin and consistent earnings beats. Recent news highlights contract wins and positive defense sector sentiment. Analyst consensus is strongly bullish with a $694.40 price target, indicating significant upside potential from current levels.
The outlook remains positive given the company's $95.61B backlog and stable cash flow generation. Key risks include political budget uncertainty and execution challenges. With solid institutional support and improving profitability metrics, NOC presents a compelling opportunity for investors seeking defense sector exposure, though geopolitical developments require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
